(Gastric Cancer) Nivolumab Can Extend Overall Survival
Medical Supporter — Information Notice
This article is a summary of international medical information and is not medical advice; it cannot replace the diagnosis or treatment plan of your attending physician. The medical technologies, drug information and clinical data presented here are compiled from public literature and official statements of major Japanese medical institutions; the applicability and outcome of any therapy vary with each patient and must be assessed individually by a qualified physician.
- November 16, 2016
- Read time: 1 minute
Ono Pharmaceutical announced on November 10 the results from the ONO-4538-12 analysis, showing that anti-PD-1 antibody nivolumab (Opdivo) can extend overall survival in unresectable advanced or recurrent gastric cancer patients who do not meet the criteria for standard treatment. The full trial results will be publicly presented at the Gastrointestinal Cancers Symposium (ASCO GI) in 2017. Please look forward to ASCO 2017!
Regarding drug information for gastric cancer, pembrolizumab (Keytruda) is currently under accelerated review. The application timeline for nivolumab (Opdivo) is not yet known, but there are high expectations for the effects of these two anti-PD-1 antibodies being used simultaneously.
For those interested, you may refer to this page from Bristol-Myers Squibb, which contains information about this clinical trial and the methods they are implementing.
About ONO-4538-12:
ONO-4538-12 is a multicenter, double-blind, randomized, placebo-controlled Phase 3 clinical trial conducted in Japan, Korea, and Taiwan, aiming to evaluate the efficacy and safety of Opdivo in patients with unresectable advanced or recurrent gastric cancer, including gastroesophageal junction cancer, refractory to or intolerant of standard therapy. In this study, Opdivo 3 mg/kg or placebo was administered every two weeks until disease progression or discontinuation due to unacceptable toxicity. The primary endpoint, overall survival, was assessed for the superiority of Opdivo versus placebo.
Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
Considering medical care in Japan? Need information and support?
We help you organize the information needed for medical travel to Japan, liaise with Japanese medical institutions, and arrange a second-opinion consultation.The first consultation is free; an advisor will help you clarify the next steps.
Figure 1
Figure 2
Figure 3
Figure 4